Porto-spleno-mesenteric venous thrombosis after elective splenectomy: a retrospective cohort study.

hematological disorders portal thrombosis porto-spleno-mesenteric venous thrombosis splenectomy splenectomy complications splenic thrombosis thrombosis screening

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 03 05 2023
accepted: 05 10 2023
medline: 7 11 2023
pubmed: 6 11 2023
entrez: 6 11 2023
Statut: epublish

Résumé

Elective splenectomy is the main treatment for a wide range of haematological diseases. Porto-spleno-mesenteric venous thrombosis represents one of the most severe complications of this procedure. The aim of this study was to evaluate risk factors associated with development of porto-spleno-mesenteric venous thrombosis after elective splenectomy. All cases of elective splenectomy carried out from April 1 Twenty-two patients (10 women, 12 men) underwent splenectomy during the study period. Indications were: immune thrombocytopenia (n: 6), myeloproliferative disorder (n: 6), hereditary spherocytosis (n: 4), thalassemia (n: 1), lymphoma (n: 1), leukaemia (n: 1), other malignancies (n: 3). Six patients developed porto-spleno-mesenteric venous thrombosis and only 2 of them were symptomatic. Patients were treated with anticoagulation therapy with complete resolution. Analysis identified three main factors associated with thrombosis: spleen diameter (p = 0.03), myeloproliferative disorder (p = 0.02), intraoperative platelet transfusion (p = 0.002) and intraoperative red blood cells transfusion (p = 0.009). Standardized postoperative screening allows prompt diagnosis and treatment of porto-spleno-mesenteric venous thrombosis even in asymptomatic cases. Patient with splenomegaly and affected by myeloproliferative disorder have a greater risk to develop this complication.

Sections du résumé

Background
Elective splenectomy is the main treatment for a wide range of haematological diseases. Porto-spleno-mesenteric venous thrombosis represents one of the most severe complications of this procedure. The aim of this study was to evaluate risk factors associated with development of porto-spleno-mesenteric venous thrombosis after elective splenectomy.
Methods
All cases of elective splenectomy carried out from April 1
Results
Twenty-two patients (10 women, 12 men) underwent splenectomy during the study period. Indications were: immune thrombocytopenia (n: 6), myeloproliferative disorder (n: 6), hereditary spherocytosis (n: 4), thalassemia (n: 1), lymphoma (n: 1), leukaemia (n: 1), other malignancies (n: 3). Six patients developed porto-spleno-mesenteric venous thrombosis and only 2 of them were symptomatic. Patients were treated with anticoagulation therapy with complete resolution. Analysis identified three main factors associated with thrombosis: spleen diameter (p = 0.03), myeloproliferative disorder (p = 0.02), intraoperative platelet transfusion (p = 0.002) and intraoperative red blood cells transfusion (p = 0.009).
Conclusion
Standardized postoperative screening allows prompt diagnosis and treatment of porto-spleno-mesenteric venous thrombosis even in asymptomatic cases. Patient with splenomegaly and affected by myeloproliferative disorder have a greater risk to develop this complication.

Identifiants

pubmed: 37928557
doi: 10.3389/fimmu.2023.1216283
pmc: PMC10625444
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1216283

Informations de copyright

Copyright © 2023 Baldari, Boni, Giuliani and Cassinotti.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

BMC Surg. 2021 Oct 12;21(1):366
pubmed: 34641842
Am J Surg. 2018 Dec;216(6):1192-1204
pubmed: 30390936
Surg Endosc. 2004 Jul;18(7):1140-3
pubmed: 15156376
Ann Surg. 1895 Jan;21(1):24-8
pubmed: 17860122
Ann Surg. 2005 Feb;241(2):208-16
pubmed: 15650628
Surg Endosc. 2010 Jul;24(7):1670-8
pubmed: 20039066
Clin Radiol. 2002 May;57(5):377-83
pubmed: 12014935
Surg Endosc. 2016 May;30(5):2119-26
pubmed: 26307597
Hepatology. 2000 Sep;32(3):466-70
pubmed: 10960436
Haematologica. 2008 Aug;93(8):1227-32
pubmed: 18556406
Surg Endosc. 2022 May;36(5):3332-3339
pubmed: 34331132
Can J Surg. 2011 Aug;54(4):227-31
pubmed: 21443837
World J Gastroenterol. 2009 Jun 28;15(24):3038-45
pubmed: 19554658
Arch Surg. 1993 Mar;128(3):341-5
pubmed: 8442693
Surgery. 2009 May;145(5):457-64; discussion 465-6
pubmed: 19375602
Gastroenterol Res Pract. 2015;2015:101029
pubmed: 26600801
Surg Endosc. 2008 Apr;22(4):821-48
pubmed: 18293036
Clin Colon Rectal Surg. 2013 Sep;26(3):153-9
pubmed: 24436666
J Laparoendosc Adv Surg Tech A. 2007 Aug;17(4):448-54
pubmed: 17705724
AJR Am J Roentgenol. 1985 Jul;145(1):73-6
pubmed: 3890495
JSLS. 2006 Apr-Jun;10(2):199-205
pubmed: 16882420
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Ultrasound. 2007 Mar;10(1):12-21
pubmed: 23396402
World J Gastrointest Endosc. 2017 Sep 16;9(9):428-437
pubmed: 28979707

Auteurs

Ludovica Baldari (L)

Department of General and Minimally-Invasive Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Luigi Boni (L)

Department of General and Minimally-Invasive Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Dipartimento di Scienze Cliniche e di Comunitá, Univeristy of Milan, Milan, Italy.

Beatrice Giuliani (B)

Department of General and Minimally-Invasive Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Elisa Cassinotti (E)

Department of General and Minimally-Invasive Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Dipartimento di Scienze Cliniche e di Comunitá, Univeristy of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH